Related Experiment Video
Updated: Jan 29, 2026

In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells
Published on: September 23, 2021
Immunogenicity of hepatitis B surface antigen derived from the baculovirus expression vector system: a mouse potency
R Attanasio1, R E Lanford, D Dilley
1Department of Virology and Immunology, Southwest Foundation for Biomedical Research, San Antonio, Texas 78228-0147.
Baculovirus-derived hepatitis B surface antigen (HBsAg) shows similar immunogenicity and antibody response duration to yeast-derived HBsAg. This suggests baculovirus-derived HBsAg is a viable alternative vaccine candidate for hepatitis B virus.
Area of Science:
- Biotechnology
- Immunology
- Virology
Background:
- Hepatitis B virus (HBV) infection is a significant global health concern.
- Recombinant vaccines are crucial for preventing HBV infection.
- The baculovirus/insect cell expression system offers a novel platform for producing vaccine antigens.
Purpose of the Study:
- To evaluate the immunogenicity of recombinant hepatitis B surface antigen (HBsAg) produced using the baculovirus/insect cell expression system.
- To compare the potency and duration of antibody response of baculovirus-derived HBsAg with a commercial yeast-derived HBsAg vaccine.
- To assess the potential of baculovirus-derived HBsAg as an alternative vaccine candidate for HBV.
Main Methods:
- A standard mouse potency test was conducted.
- NIH Swiss mice were immunized with serial four-fold doses of either baculovirus-derived HBsAg or yeast-derived HBsAg.
- Antibody response (anti-HBs) was measured at various time points post-immunization.
Main Results:
- The effective dose required to seroconvert 50% of animals was similar for both baculovirus- and yeast-derived HBsAg.
- No decrease in anti-HBs response was observed 6 months after immunization with either vaccine preparation.
- The antibody response duration indicates sustained immunogenicity for both vaccine types.
Conclusions:
- Baculovirus-derived recombinant HBsAg demonstrates comparable immunogenicity to yeast-derived HBsAg.
- The sustained antibody response suggests long-term protection potential.
- Baculovirus-derived HBsAg presents a promising alternative vaccine candidate for hepatitis B virus prevention.
Related Concept Videos
Vectors
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Source And Potency Of Stem Cells
Hepatic Portal System
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
Dose-Response Relationship: Potency and Efficacy

